[ad_1]
World
GlaxoSmithKline announced Monday that an advanced-stage study testing Zejula as a maintenance treatment in patients with first-line ovarian cancer had shown positive results.
The GlaxoSmithKline logo (GSK) is visible on the GSK Asia House in Singapore, March 21, 2018. Photo taken on March 21, 2018. REUTERS / Loriene Perera
marker
REUTERS: GlaxoSmithKline announced Monday that a final-phase study testing Zejula as a maintenance treatment in patients with first-line ovarian cancer had shown positive results .
GSK agreed to buy its US $ 5.1 billion cancer specialist, Tesaro, in December, giving it a marketed product for ovarian cancer, Zejula, which belongs to a promising clbad of drugs.
The drug maker said the study met its primary goal of a statistically significant improvement in progression-free survival among women, regardless of their biomarker status.
(Report of Noor Zainab Hussain in Bengaluru, edited by Arun Koyyur)
Source link
